Vinge advised Cantargia on the deal. Cantargia AB (publ) secured a rights offering of approximately SEK 170 million. Cantargia develops antibody based therapies against the target...
You must be a Standard 1 Year member to access this content.
Vinge advised Cantargia AB on the deal. Cantargia AB (publ) completed a directed share issue of approximately SEK 59 million (approx. $5.4 million) to a number of...
You must be a Standard 1 Year member to access this content.
Vinge advised Cantargia AB on the deal. Cantargia AB announced a fully covered new share issue of approximately SEK 250 million with pre-emptive rights for the Company’s...
You must be a Standard 1 Year member to access this content.
